The Patent Finder

INDAZOLE-3-Carboxamides AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS

Biosplice Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 61/534,601, filed Sep 14, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,697,887INDAZOLE-3-Carboxamides and Their Use as Wnt/Beta-Catenin Signaling Pathway Inhibitors
In force
 · Medium confidence
UsedRemaining
Biosplice Therapeutics, Inc.In forceMedium confidence
US 9,802,916INDAZOLE-3-Carboxamides and Their Use as Wnt/Beta-Catenin Signaling Pathway Inhibitors
In force
 · Medium confidence
Biosplice Therapeutics, Inc.In forceMedium confidence
US 10,464,924INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors
In force
 · Medium confidence
Biosplice Therapeutics, Inc.In forceMedium confidence
US 11,066,388INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors
In force
 · Medium confidence
Biosplice Therapeutics, Inc.In forceMedium confidence
US 11,780,823INDAZOLE-3-Carboxamides and Their Use as Wnt/B-Catenin Signaling Pathway Inhibitors
In force
 · Medium confidence
Biosplice Therapeutics, Inc.In forceMedium confidence
US 9,221,793INDAZOLE-3-Carboxamides AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
In force
 · Medium confidence
Biosplice Therapeutics, Inc.In forceMedium confidence
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited